Clin Lab. 2022 Feb 1;68(2). doi: 10.7754/Clin.Lab.2021.210623.
Limited data are available regarding intraindividual changes in the Mac-2 binding protein glycosylation isomer (M2BPGi), a liver fibrosis biomarker, performed for health checkups in Korean subjects.
Through a laboratory information system, we retrospectively investigated longitudinally measured M2BPGi to assess intraindividual changes in M2BPGi test results.
During a 38-month study period, 526 test results from 246 Korean subjects undergoing general health checkups were requested from 13 local clinics and hospitals. Among all 246 subjects, 190 (77.2%) exhibited negative M2BPGi (< 1.0 C.O.I.) during the initial measurement. Among all 246 subjects, 210 (85.4%) did not experience any changes in qualitative results during a follow-up. Among 42 subjects with initially 1+ positive results for M2BPGi, 17 (40.5%) changed to a negative M2BPGi result at least once during follow-up. No subjects with initially negative results or 1+ positive (1.0 ≤ C.O.I. < 3.0) results changed to 2+ positive (≥ 3.0 C.O.I.) results during the 38-month follow-up period.
Some subjects exhibited qualitative changes in M2BPGi during follow-up health examinations. Future studies are needed to clarify the clinical implication of such changes.
关于健康检查中个体内肝纤维化生物标志物 M2BPGi（Mac-2 结合蛋白糖基化异构体）的糖化异构体变化，目前仅有有限的数据。
通过实验室信息系统，我们回顾性地纵向测量了 M2BPGi，以评估 M2BPGi 检测结果的个体内变化。
在 38 个月的研究期间，从 13 家当地诊所和医院请求了 246 名韩国受试者进行一般健康检查的 526 项测试结果。在所有 246 名受试者中，190 名（77.2%）在初始测量时表现出 M2BPGi 阴性（<1.0 C.O.I.）。在所有 246 名受试者中，210 名（85.4%）在随访期间定性结果没有任何变化。在最初 M2BPGi 检测结果为 1+阳性的 42 名受试者中，有 17 名（40.5%）至少在随访期间有一次转为阴性 M2BPGi 结果。在 38 个月的随访期间，没有最初结果为阴性或 1+阳性（1.0 ≤ C.O.I. < 3.0）的受试者转变为 2+阳性（≥3.0 C.O.I.）。
一些受试者在随访健康检查中表现出 M2BPGi 的定性变化。需要进一步的研究来阐明这些变化的临床意义。
